Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment

References

• Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage: proceedings of an expert panel roundtable discussion. Retina. 2006;Suppl:1–16. doi:10.1097/01.iae.0000250601.15893.5f
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136–1145.e5. doi:10.1016/j.ajo.2014.09.003
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339
   PubMed Web of Science ®Google Scholar
• Steeples LR, Anand N, Moraji J, Jones NP. Clinical outcomes of intravitreal preservative-free triamcinolone preparation (Triesence®) for cystoid macular oedema and inflammation in patients with uveitis. Ocul Immunol Inflamm. 2018;26(7):997–1004. doi:10.1080/09273948.2017.1294185
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Robinson MR. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. Ann N Y Acad Sci. 2015;1358(1):1–12. doi:10.1111/nyas.12824
   Web of Science ®Google Scholar
• Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019;126(2):283–295. doi:10.1016/j.ophtha.2018.08.021
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191–1201. doi:10.1001/archopht.126.9.1191
   PubMedGoogle Scholar
• Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2015;4:1. doi:10.1007/s40123-014-0027-6
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–1027. doi:10.1016/j.ophtha.2006.02.021
   PubMed Web of Science ®Google Scholar
• Retisert Prescribing Information.Bausch and Lomb. Available from: https://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/retisert-fluocinolone-acetonide-intravitreal-implant-059-mg#.YAM1ZC90c1I. Accessed January 16 2021.
   Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–1926. doi:10.1016/j.ophtha.2011.07.027
   PubMed Web of Science ®Google Scholar
• Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117(3):567–575.e1. doi:10.1016/j.ophtha.2009.11.027
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125(11):1478–1485. doi:10.1001/archopht.125.11.ecs70063
   PubMedGoogle Scholar
• Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–1948. doi:10.1016/j.ophtha.2016.05.025
   PubMed Web of Science ®Google Scholar
• Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after RetisertTM intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004;20(3):269–275. doi:10.1089/1080768041223611
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107(11):2024–2033. doi:10.1016/S0161-6420(00)00466-8
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–587. doi:10.1016/j.ophtha.2012.09.014
   PubMed Web of Science ®Google Scholar
• Testi I, Pavesio C. Preliminary evaluation of YUTIQTM (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. Ther Deliv. 2019;10(10):621–625. doi:10.4155/tde-2019-0051
   PubMed Web of Science ®Google Scholar
• Alimera Sciences Limited. Summary of product characteristics for ILUVIEN 190 micrograms intravitreal implant in applicator. Medicine and Healthcare Products Regulatory Agency I 190 micrograms intravitreal implant in applicator: summary of product characteristics. 2012. Available from: https://www.medicines.org.uk/emc/medicine/27636#gref. Accessed January 16 2021.
   Google Scholar
• Overview Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | NICE Guidance. 2019. Available from: https://www.nice.org.uk/guidance/ta590. Accessed January 16 2021.
   Google Scholar
• EyePoint Pharmaceuticals US. YUTIQ: prescribing information. .2018. Available from: www.eyepointpharma.com/wp-content/uploads/2019/01/YUTIQ-USPI-20181120.pdf. Accessed January 16 2021.
   Google Scholar
• Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March. 2009. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009. Accessed January 16 2021.
   Google Scholar
• EyePoint. Safety and efficacy of an injectable fluocinolone acetonide insert. NLM identifier NCT01694186. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01694186. Accessed January 16 2021.
   Google Scholar
• EyePoint. Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) insert in subjects with chronic non-infectious posterior uveitis. NLM identified NCT02746991. Available from: https://clinicaltrials.gov/ct2/show/NCT02746991. Accessed January 16 2021.
   Google Scholar
• Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–610. doi:10.1016/j.ophtha.2018.10.033
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Pavesio CE. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology. 2020;127(10):1395–1404. doi:10.1016/j.ophtha.2020.04.001
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Biswas J, Paggiarino DA FAi insert treatment for noninfectious posterior uveitis: three-year results of a confirmatory trial. Abstract paper PA063. American Academy of Ophthalmology Annual Meeting Nov 2020. Available from: https://secure.aao.org/aao/meeting-archive. Accessed 16 January 2021.
   Google Scholar
• EyePoint Pharmaceuticals. Press release 36-month follow up data for phase 3 study of YUTIQ. Available from: http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-positive-topline-36-month. Accessed 16 January 2021.
   Google Scholar
• Cai CX, Skalak C, Keenan RT, Grewal DS, Jaffe GJ. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Graefe’s Arch Clin Exp Ophthalmol. 2020;258(5):1023–1030. doi:10.1007/s00417-020-04614-x
   PubMed Web of Science ®Google Scholar
• Weber LF, Marx S, Auffarth GU, et al. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. 2019;9(1). doi:10.1186/s12348-019-0168-9
   Web of Science ®Google Scholar
• Pockar S, Leal I, Chhabra R, Jones NP, Steeples LR Injectable fluocinolone acetonide implant in non-infectious uveitis: 6-month outcomes from a single UK tertiary centre. Euretina 2020 Virtual Conference, October 2020. Poster abstract. Available from: https://www.euretina.org/congress/amsterdam-2020/virtual-2020-posters/?type=2. Accessed 16 January 2021.
   Google Scholar
• Andrews HW, Ganaputra S, Hamdan S, Kim SJ Real-world therapeutic efficacy of fluocinolone acetonide 0.18 mg injectable intravitreal implant in chronic uveitis. Abstract Paper PA066. American Academy of Ophthalmology Annual Meeting, Nov 2020. Available from: https//secure.aao.org/aao/meeting-archive. Accessed January 12, 2021.
   Google Scholar
• Ajamil-Rodanes S, Testi I, Luis J, Robson AG, Westcott M, Pavesio C. Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis. Br J Ophthalmol. 2020. doi:10.1136/bjophthalmol-2020-317372
   Web of Science ®Google Scholar
• Rush RB, Goldstein DA, Callanan DG, Meghpara B, Feuer WJ, Davis JL. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol. 2011;151(4):630–636. doi:10.1016/j.ajo.2010.10.005
   PubMed Web of Science ®Google Scholar
• Bajwa A, Aziz K, Foster C. Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy. Retina. 2014;34(11):2259–2268. doi:10.1097/IAE.0000000000000239
   PubMed Web of Science ®Google Scholar
• Vieira R, Sousa-Pinto B, Figueira L. Efficacy and safety of corticosteroid implants in non-infectious uveitis: a systematic review with network meta-analysis. Ocul Immunol Inflamm. 2020;18(1–8):onlineahead of print. doi:10.1080/09273948.2020.1787463
   Web of Science ®Google Scholar